First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Total Non-current Assets
All assets not expected to be converted to cash within one year.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets remains negative
Q1 FY2026 total non-current assets was $1.17M, compared with $0 a year earlier.
Context
- Total non-current assets amounted to 0.4% of total assets at the end of Q1 FY2026.
- Total non-current assets increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 14.15M USD
- Year-over-year change
- -72.8%
- 2-year CAGR
- -44.3%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.15M | -72.8% |
| FY2024 | 2024-12-31 | 51.96M | +14.1% |
| FY2023 | 2023-12-31 | 45.55M | — |
Total Non-current Assets vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 total non-current assets of $1.17M is the 8th highest of the 10 companies compared; the peer median is $13.58M.
- Total non-current assets amounts to 0.4% of total assets for TRAX, versus a peer median of 7.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $130.27M | +525.7% | +35.6% | 54.7% | |
| Mar 2026 | $88.49M | -0.9% | -26.6% | 44.5% | |
CLYMClimb Bio, Inc. | Mar 2026 | $38.97M | -61.2% | +369.3% | 25.6% |
| Mar 2026 | $33.09M | -1.5% | +0.0% | 22.6% | |
| Mar 2026 | $13.58M | -77.0% | -55.7% | 4.1% | |
| Jun 2026 | $9.95M | — | — | 7.8% | |
| Mar 2026 | $3.73M | -25.3% | +102.1% | 0.9% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $1.17M | — | — | 0.4% |
| Mar 2026 | $983K | -36.2% | -14.4% | 0.5% | |
| Sep 2026 | $921K | -90.2% | +79.8% | 0.1% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $13.58M | -30.7% | +17.8% | 7.8% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.